Literature DB >> 12804727

Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome.

Nathan D Wong1, Jose R Pio, Stanley S Franklin, Gil J L'Italien, Tripthi V Kamath, G Rhys Williams.   

Abstract

We estimated the coronary heart disease (CHD) events that are preventable by treatment of lipids and blood pressure in patients with metabolic syndrome (MetS), a contributor to coronary heart disease (CHD). Among patients aged 30 to 74 years (without diabetes or CHD) in the United States, MetS was defined by National Cholesterol Education Program criteria. CHD events over a period of 10 years were estimated by Framingham algorithms. Events that could be prevented by statistically "controlling" blood pressure, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol to either normal or optimal levels according to national guidelines were calculated. Of 7.5 million men and 9.0 million women aged 30 to 74 years with MetS, approximately 1.5 million men and 0.45 million women, if untreated, developed CHD events in 10 years. In men and women, blood pressure control to normal levels "prevented" 28.1% and 12.5% of CHD events, respectively (p <0.01); control to optimal levels resulted in preventing 28.2% and 45.2% of events, respectively (p <0.01). Control of HDL cholesterol to normal levels resulted in preventing 25.3% of events in men and 27.3% in women; optimal control prevented 51.2% and 50.6% of events, respectively. Control of LDL cholesterol to normal levels prevented 9.3% of events in men and 9.8% of events in women; control to optimal levels prevented 46.2% and 38.1% of events (p <0.05), respectively. Control of all 3 risk factors to normal levels resulted in preventing 51.3% of events for men and 42.6% for women; control to optimal levels resulted in preventing 80.5% and 82.1% of events, respectively. Thus, many CHD events in patients with MetS may be preventable by nominal or optimal control of lipids and/or blood pressure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804727     DOI: 10.1016/s0002-9149(03)00392-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  27 in total

1.  Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988-2010.

Authors:  Brent M Egan; Jiexiang Li; Suparna Qanungo; Tamara E Wolfman
Journal:  Circulation       Date:  2013-07-02       Impact factor: 29.690

2.  Study of the Use of Lipid Panels as a Marker of Insulin Resistance to Determine Cardiovascular Risk.

Authors:  Ruth Ann Bertsch; Maqdooda A Merchant
Journal:  Perm J       Date:  2015

3.  Difficulties in achieving arterial hypertension control.

Authors:  Genel Sur; Maria Sur; Liana Kudor-Szabadi; Lucia Sur
Journal:  Maedica (Buchar)       Date:  2011-04

Review 4.  Intracranial atherosclerotic stroke: specific focus on the metabolic syndrome and inflammation.

Authors:  Oh Young Bang
Journal:  Curr Atheroscler Rep       Date:  2006-07       Impact factor: 5.113

Review 5.  Statins and the primary prevention of cardiovascular events.

Authors:  Michael Clearfield
Journal:  Curr Atheroscler Rep       Date:  2006-09       Impact factor: 5.113

6.  Arterial hypertension - prevalence of risk factors and morbide associations that increase cardiovascular risk.

Authors:  G Sur; M Sur; L Kudor-Szabadi; L Sur; D Sporis; D Sur
Journal:  Maedica (Buchar)       Date:  2010-01

Review 7.  Assessment of cardiovascular risk and choice of antihypertensive therapy.

Authors:  William B Kannel; Ramachandran S Vasan
Journal:  Curr Hypertens Rep       Date:  2004-10       Impact factor: 5.369

8.  Effects of the DASH diet on blood pressure in patients with and without metabolic syndrome: results from the DASH trial.

Authors:  Fadi Hikmat; L J Appel
Journal:  J Hum Hypertens       Date:  2013-09-26       Impact factor: 3.012

Review 9.  Prehypertension: risk stratification and management considerations.

Authors:  Brent M Egan; Stevo Julius
Journal:  Curr Hypertens Rep       Date:  2008-10       Impact factor: 5.369

10.  Estimating cardiovascular risk in patients with type 2 diabetes: a national multicenter study in Brazil.

Authors:  Marilia B Gomes; Daniel Giannella-Neto; Manuel Faria; Marcos Tambascia; Reine M Fonseca; Rosangela Rea; Geisa Macedo; João Modesto-Filho; Helena Schmid; Alcina V Bittencourt; Saulo Cavalcanti; Nelson Rassi; Hermelinda Pedrosa; Sergio A Dib
Journal:  Diabetol Metab Syndr       Date:  2009-10-27       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.